MNMasatoshi Nakamura

Masatoshi Nakamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masatoshi Nakamura has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Hideyuki Sakurai

    Department of Radiation Oncology, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan

    2 shared publications
  • Shohei Taguchi

    Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Higashi-Ku, Japan

    2 shared publications
  • Akane Nagasato

    Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University

    1 shared publication
  • Alison Fitzgerald

    Division of Clinical Operations, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA

    1 shared publication
  • Hidetoshi Kamimura

    Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University

    1 shared publication
  • Hiroko Fukushima

    Department of Pediatrics University of Tsukuba Hospital Tsukuba Japan

    1 shared publication

Latest Publications

  • Open Access

    A systematic review and meta-analysis of radiotherapy and particle beam therapy for skull base chondrosarcoma: TRP-chondrosarcoma 2024

    by Masatoshi Nakamura, Masashi Mizumoto, Takashi Saito, Shosei Shimizu, Yinuo Li, Yoshiko Oshiro, Masako Inaba, Sho Hosaka, Hiroko Fukushima, Ryoko Suzuki, et al.

    Introduction: Chondrosarcoma is a rare malignant bone tumor. Particle beam therapy (PT) can concentrate doses to targets while reducing adverse events. A meta-analysis based on a literature review was performed to examine the efficacy of PT and photon radiotherapy for skull base chondrosarcoma.Methods: The meta-analysis was conducted using 21 articles published from 1990 to 2022.Results: After PT, the 3- and 5-year overall survival (OS) rates were 94.1% (95% confidence interval [CI]: 91.0-96.2%) and 93.9% (95% CI: 90.6-96.1%), respectively, and the 3- and 5-year local control rates were 95.4% (95% CI: 92.0-97.4%) and 90.1% (95% CI: 76.8-96.0%), respectively. Meta-regression analysis revealed a significant association of PT with a superior 5-year OS rate compared to three-dimensional conformal radiotherapy (p < 0.001). In the studies used in the meta-analysis, the major adverse event of grade 2 or higher was temporal lobe necrosis (incidence 1-18%, median 7%).Conclusion: PT for skull base chondrosarcoma had a good outcome and may be a valuable option among radiotherapy modalities. However, high-dose postoperative irradiation of skull base chondrosarcoma can cause adverse events such as temporal lobe necrosis.


  • Open Access

    Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study

    by Masaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, Reiko Sakaguchi, Keisuke Okamoto, Yongcai Mao, Joyce Tsai, Alison Fitzgerald, Kentaro Takai, Teruhiko Higuchi

    Purpose: The goal of this study was to evaluate the safety and effectiveness of lurasidone among patients with schizophrenia in a 12-week open-label extension study. Patients and Methods: Patients who completed a 6-week, double-blind, placebo-controlled study were enrolled in a 12-week open-label extension study with flexible dosing of lurasidone at 40 or 80 mg/day. Safety assessments included adverse events, vital signs, laboratory tests, and electrocardiogram (ECG) parameters. Effectiveness measures included the Positive and Negative Syndrome Scale (PANSS) total score, Clinical Global Impression-Severity Scale (CGI-S), Calgary Depression Scale for Schizophrenia (CDSS) and quality of life measure. Results: A total of 289 patients were enrolled in the open-label extension study. Rates of treatment-emergent adverse events (TEAEs) were low; akathisia was the most common TEAE with an incidence of 6.6%. There were 54 patients (18.7%) who discontinued the extension study, with 17 (5.9%) discontinuing due to adverse events. Minimal or no effects of lurasidone on weight, body mass index, metabolic parameters, prolactin, and ECG parameters were evident. There was continued improvement to week 12 in PANSS and CGI-S scores beyond the initial gains made during the prior 6-week double-blind study. Non-responders to lurasidone 40 mg/day in the prior 6-week study showed a mean (standard deviation) improvement from open-label baseline of 10.7 (13.8) points on the PANSS total score after lurasidone dose was increased to a modal dose of 80 mg/day during the extension study. Changes from double-blind baseline in CDSS and quality of life were maintained in the extension study. Conclusion: Treatment with lurasidone 40 or 80 mg once daily (flexibly dosed) continued to be well tolerated with patients demonstrating further improvement in symptoms over the course of a 12-week open-label extension study in patients with schizophrenia.


  • Open Access

    Efficacy and Safety of Caffeine for Preterm Infants with Apnea According to Birth Weight

    by Akane Nagasato, Tomomi Kuramitsu, Masatoshi Nakamura, Hidetoshi Kamimura

    Apnea of prematurity is one of the most common problems in preterm and low birth weight infants, and it is reported to be more likely to occur in infants of lower gestational age and lower birth weight. The present study investigated the efficacy and safety of caffeine according to weight, based on birth weight. We defined preterm infants with birth weights of < 1,000 g, 1,000 g to < 1,500 g, and 1,500 g to < 2,500 g as the extremely low birth weight (ELBW), very low birth weight (VLBW), and low birth weight (LBW) groups, respectively. There was a significant difference among the three groups in the rate of improvement of apnea attacks from days 1 to 10 of administration. The percentage of cases that showed “improvement” on each day tended to be higher in the LBW group. The incidence of adverse events was 100% in the ELBW group, 90.9% in the VLBW group, and 64.7% in the LBW group (P < 0.001). However, regarding adverse events that were suspected to have been caused by caffeine or events that required dose reduction or discontinuation of caffeine due to adverse events, there were no significant differences among the three groups in any of the items that were investigated. These results suggest that the greater the birth weight, the more likely effects of treatment will occur, and that although careful administration is required, the administration of caffeine to infants of lower birth weight may be feasible.


  • Open Access

    Salvage Photon or Proton Radiotherapy for Oligo-recurrence in Regional Lymph Nodes After Surgery for Non-small Cell Lung Cancer

    by Masatoshi Nakamura, Kayoko Ohnishi, Hitoshi Ishikawa, Kensuke Nakazawa, Toshihiro Shiozawa, Toshiyuki Okumura, Ikuo Sekine, Yukio Sato, Nobuyuki Hizawa, Hideyuki Sakurai

    Background/Aim: To evaluate the outcome of definitive salvage radiotherapy (RT) in non-small cell lung cancer (NSCLC) patients with oligo-recurrence in regional lymph nodes after surgery. Patients and Methods: Between January 2003 and December 2016, 33 patients with NSCLC were reviewed from radiotherapy database at our hospital. All patients received photon or proton salvage RT for metastases in the regional lymph nodes. Results: The median follow-up from salvage RT was 35.2 (range=5.9-89.6) months. Recurrences occurred in 18 (55%) patients, and the 3-year overall and progression-free survival rates were 63.8% and 45.1%, respectively. Regional and local control improved patients' survival and these control rates were increased by use of concurrent chemotherapy (p=0.039) and proton RT (p=0.084). No grade 4 acute or late non-hematologic toxicities were observed. Conclusion: Salvage RT is an effective treatment for NSCLC patients with oligo-recurrence at regional lymph nodes.


  • Association of lymphocyte crossmatch and the outcome of intestinal transplantation in swine

    by Makoto Hayashida, Toshiharu Matsuura, Isamu Saeki, Yusuke Yanagi, Koichiro Yoshimaru, Yuko Nishimoto, Yukiko Takahashi, Keiko Fujita, Narito Takada, Shohei Taguchi, et al.

    Background The effect of preformed antidonor antibodies have been demonstrated in various types of solid organ transplantation. However, the significance of anti-donor antibodies in intestinal transplantation remains unclear. The aim of this study is to evaluate the impact that the extent of T cell crossmatch has on the outcome of swine intestinal transplantation. Materials and methods All studies were performed on outbred domestic male pigs weighing from 15 to 20 kg. Intestinal transplantation was performed orthotopically with an exchange of grafts between white and black pigs. FK506 was administered intravenously (0.1 mg/kg per day, POD 0–7) for immunosuppression. A lymphocyte crossmatch test was performed using the direct CDC crossmatch. The results were considered positive when more than 10% of the donor lymphocytes were killed by the recipient’s serum. In addition, 0–10, 11–20, 21–30, 31–80 and 81–100% of the killed lymphocytes were classified as grade 1, 2, 4, 6 and 8, respectively. Result A total of 34 intestinal transplantations were performed. All but one case had positive donor specific T cell crossmatches. The number of grade 2, 4, 6 and 8 cases was 11, 14, 6 and 2, respectively. Although there was a tendency towards a decreased survival according to the grade, the survival rate was not statistically different among each different grade. Moreover, the rates of acute cellular rejection and vascular complications were not significantly different among the four grades. Conclusion These results suggest that the extent of positive T cell crossmatch is not associated with the outcome of swine intestinal transplantation.


  • Changing profile of parenteral nutrition in pediatric surgery: A 30-year experience at one institute

    by Sachiyo Suita, Takeshi Yamanouchi, Koji Masumoto, Keiko Ogita, Masatoshi Nakamura, Shohei Taguchi